IMHO (the 'H' represents Humble), Cynata suffers the same issue that Mesoblast did (and to a lesser extent still does).
These are excellent results and as a retail shareholder, I am truly impressed. I can see what they are saying and it is very exciting.
But, here's the thing......
They need to impress their peers. Peers with lots of money to partner (the best kind of peers).
Because of Mesoblast being first to market, there was reluctance. That reluctance has now been removed for all MSC companies.
CYP says this:
I agree wholeheartedly!
Given that MSCs have been approved for GVHD, how have you not delivered a partner from YOUR PEERS that know more than retail investors? Wouldn't this news be the final nail in the coffin of ALL THE BD THAT YOU HAVE BEEN DOING FOR YEARS?
This is a rod for the CYP management's own back.
The objective of Cynata BoDs is not to deliver good/great reports. Since the FDA approval, those days are over for both Cynata and Mesoblast.
They both talk it like they realise but why don't they just deliver on the talk?
If they don't deliver then they are incompetent. Can anyone show me a flaw in my logic?
The game changed with the FDA approval.
CYP Price at posting:
24.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)